Clinical trials: Stem Cell Transplantation
Non-Hodgkin's Lymphoma, CNS Lymphoma
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Current standard treatments for lymphoma involving the central nervous system include chemotherapy or whole brain radiation therapy (WBRT).
- Trial name
- NCT01182415
- Testing
- Autologous stem cell transplant, High-dose chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Graft vs Host Disease, Hematologic Neoplasms
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
This protocol, UMCC 2012.047, was a pilot study initially intended for 12 subjects. After completing enrollment of the planned 12 subjects, we are extending the study to an additional 25 subjects.
- Conditions
- Graft vs Host Disease, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder
- Trial name
- NCT01790568
- Testing
- Vorinostat, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
Stem Cell Transplant for Immunologic or Histiocytic Disorders
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of…
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome
- Trial name
- NCT00176865
- Testing
- Stem Cell Transplant, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: efprezimod alfa vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- CATHY (NCT04095858)
- Testing
- Efprezimod alfa, Methotrexate, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Myeloid Leukemia, Allogeneic Hematopoietic Cell Transplantation
A Study of FMT in Patients With AML Allo HSCT in Recipients
This is a randomized, double-blind, placebo-controlled clinical trial of Fecal Microbiota Transplant (FMT) in 2 independent cohorts (60 acute myeloid leukemia patients undergoing intensive chemotherapy and 60 Allo-HCT patients).
- Trial name
- NCT03678493
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Leukemia, Hodgkin Lymphoma
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and…
- Conditions
- Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT00556452
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan Rogel Cancer Center
Stem Cell Transplantation, Myelodysplastic Syndromes
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing…
- Conditions
- Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT05968963
- Testing
- Mindfulness-based Music Therapy (MBMT), Mindfulness Meditation (MM)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Miami
Immune Deficiency Disorders, Severe Combined Immunodeficiency
Immune Disorder HSCT Protocol
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders.
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia
- Trial name
- NCT01821781
- Testing
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Blood disorders such as leukemia or lymphoma or hemoglobinopathies can benefit from receiving an allogeneic (meaning that the cells are from a donor) stem cell transplant. Stem cells are created in the bone marrow.
- Conditions
- Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00579111
- Testing
- Campath, Busulfan, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Leukemia, Myeloid, Chronic, AML
Stem Cell Transplant for Hematological Malignancy
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood.
- Conditions
- Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS
- Trial name
- NCT00176930
- Testing
- Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and…
- Trial name
- NCT02989844
- Testing
- N-803
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Graft Versus Host Disease
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant.
- Trial name
- NCT02144701
- Testing
- Lactobacillus rhamnosus GG, laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Rutgers, The State University of New Jersey
Sarcoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with peripheral stem cell transplantation may allow…
- Trial name
- NCT00002601
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Hematologic Neoplasms
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating cancers of the blood and immune system.
- Trial name
- NCT00051311
- Testing
- Stem cell transplantation, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00445692
- Testing
- Clarithromycin, Dexamethasone, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants…
- Trial name
- NCT02728895
- Testing
- Vedolizumab
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.